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Introduction
Esophageal squamous cell carcinoma (ESCC) is rela-
tively rare in Poland – it was the thirteenth most com-
mon tumor in males and the thirty third in females
according to registered incidence of malignances in
2002 [1]. However, both in Poland and in rest of the
world, it is regarded as one of the most lethal neo-
plasm. At present, a 5-year survival for the whole
group of patients with this cancer is about 15% despite
great progress in early detection of precursor lesions
and early cancers, especially in high-risk populations,
along with application of better methods of therapy
(advances in surgical and endoscopic techniques,
neoadjuvant chemo- and/or radiotherapy, etc.). The
poor prognosis is mostly the result of advanced stage
at presentation, which excludes over 50% of patients
from curative treatment [2]. An aggressive clinical
behavior of ESCC is a consequence of its high local
invasiveness and metastatic potential [3]. These
processes are complex but in a simplistic picture, are
involved in detachment of neoplastic cells from the
primary site, penetration of extracellular matrix
(ECM), followed by entrance into the lumen of ves-
sels, migration with lymph or blood, extravasation into
distant organs, and growth with formation of second-
ary tumors [4]. In fact, each step of this cascade of
events depends on a variety of cell-cell or cell-matrix
interactions mediated by major families of cell adhe-
sion molecules (CAMs) i.e., cadherins, integrins,
immunoglobulins, and selectins, however, some others
macromolecules like syndecans are also engaged [4,5].
Syndecans are a four-member family of integral
membrane heparan sulfate proteoglycans. They are
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ubiquitous molecules and individual cell types or tis-
sues are characterized by distinct pattern of syndecans
expression [5]. Due to the localisation and structure of
syndecans they interact with many macromolecules
including growth factors (e.g., fibroblast growth factor
– FGF, hepatocyte growth factor – HGF, vascular
endothelial growth factor – VEGF), ECM components
(e.g., fibronectin, vitronectin, laminins and the fibrillar
collagens) or cell-cell adhesion molecules (e.g., L-
selectin, platelet-endothelial cell adhesion molecules –
PECAM-1, Mac-1) and via CASK (calcium/calmod-
ulin-dependent serine protein kinase), α-actinin and
family of actin-binding proteins containing FERM
domain with actin cytoskeleton. In this fashion, they
may influence a variety of cellular functions like:
adhesion, cell signaling, growth, differentiation and
motility both, in physiologic and pathologic conditions
[5,6]. Recent changes in the syndecans' expression,
including the best characterized syndecan-1 (CD138),
revealed in many precursor lesions and carcinomas are
believed to contribute to their progression [6]. 
The other important aspect of tumor spread is
destruction of ECM as a consequence of secretion of
different proteolytic enzymes i.e., cysteine-, serine-
and aspartic proteases, as well as matrix metallopro-
teases, by tumor or stromal cells. Enzymes breakdown
components of ECM including basement membrane
that allows for the formation of passageways for the
migration of neoplastic cells [7]. Cathepsins D (EC
3.4.23.5) and K (EC 3.4.22.38) are lysosomal proteas-
es that belong to different classes of endopeptydases,
i.e., aspartic and cysteine ones respectively [8,9].
Cathepsin D, detected in most human cells, plays an
important role in the intracellular catabolism of pro-
teins, direct degradation of ECM components, the acti-
vation of precursor forms of some proteases, and the
inactivation of their inhibitors. It may stimulate epithe-
lial cell proliferation by binding insulin-like growth fac-
tor receptor (IGFR) and by activation/liberation of other
growth factors from ECM. Cathepsin D is also associat-
ed with p53-dependent apoptosis, angiogenesis, and
attenuation of anti-tumor immune response [7,8]. The
enzyme is now regarded as an important factor promot-
ing tumor growth and spread in many malignances [7].
On the contrary, cathepsin K is characterised by
strong collagenolytic and elastinolytic activities [9]. Its
expression was revealed in osteoclasts participating in
bone and cartilage physiological remodelling. Further-
more, the enzyme was also detected in some epithelial
cells e.g., of breast, thyroid gland and lung, where it is
engaged is their normal development and function
including extracellular proteolysis of e.g., thyreoglob-
ulin or ECM turnover [9-11]. Nowadays, cathepsin K
is considered as an important factor in pathogenesis of
many inflammatory disorders and neoplasms, not sole-
ly of the skeletal system [9,12,13]. 
Since the role of syndecan-1 and cathepsins D and
K in esophageal ESCC remains unclear, the aim of the
present study was to determine the immunoexpression
of these proteins and to analyse their relationship to the
selected clinicopathological features and survival. 
Materials and methods
Patients characteristic. The study comprised 39 patients with
advanced squamous cell carcinoma of the middle thoracic part of
the esophagus. All patients were treated by surgery alone at the 2nd
Department of General Surgery, Medical University of Lublin,
Poland from March 1995 to February 2001. Transthoracic subtotal
esophagectomy with 3-D lymph nodes dissection was performed in
32 patients (82.05%) and transhiatal esophagectomy without thora-
cotomy in remaining 7 cases (17.94%). The study group consisted of
36 men (92.31%) and 3 women (7.69%) of ages, ranging from 36 to
75 years (mean 57.74; median 57). The follow-up time ranged from
3 to 68 months (mean 16.13; median 12.0). All the patients deceased
by the end of December 2003. Analysis of factors related to survival
was limited to one-year observation, due to the overall short survival
time in the study group. Ten patients were excluded from this analy-
sis since they died within 30 days after the surgery. 
Pathological study. The surgical specimens were fixed in 10%
buffered formalin. The sections were taken according to standard
protocol (3-8 sections of the tumor, 2 sections of normal-appearing
esophageal wall, sections of proximal and distal resection margins,
and sections of all resected lymph nodes – 2-75/case). The sections
were routinely processed, embedded in paraffin blocks, and stained
with hematoxylin and eosin. Evaluation of pathologic stage of the
disease was based on the TNM system and the grade of tumor dif-
ferentiation on the World Health Organization's criteria [14].
Tumor growth pattern were assessed as expansive (well-circum-
scribed, pushing border) or infiltrative (indistinct, irregular bor-
der). Presence of lymphatic/vascular invasion was defined as
tumor cells located within distinct endothelial-lined spaces and
partly attached to the lining (no accessory techniques of visualiza-
tion were applied) [15]. Prominent desmoplasia was defined as
desmoplastic stroma compassing >50% of tumor area. Distinct cuff
of lymphocytes in direct vicinity of advancing edges of the tumor
was regarded as prominent peritumoral lymphocytic response. Fur-
thermore, the presence of perineural invasion was also noted. 
Immunohistochemical study. An immunohistochemical study
was performed on 3 μm sections from one, representative paraffin
block from each primary tumor. For syndecan-1 and cathepsin D
the antigen retrieval technique was applied and slices were pre-
treated in citrate buffer (0.01 M, pH 6.0) in a microwave oven (2x
for 5 min at 750 W). For all antigens the endogenous peroxidase
activity was blocked by 3% hydrogen peroxide solution for 20
minutes at room temperature. To block non-specific binding sites
normal goat or rabbit serum was applied for 10 minutes at room
temperature for syndecan-1 and cathepsin D, respectively. This
procedure was omitted for the cathepsin K reaction. In the next
step, the sections were incubated with the following primary mon-
oclonal mouse anti-human antibodies against: syndecan-1
(CD138) (clone B-B4, Serotec, UK; dilution 1:100 for 30 min),
cathepsin D (clone C5, Novocastra, UK; dilution 1:100 for 60
min), and cathepsin K (clone CK4, Novocastra; dilution 1:80 for
60 min) at room temperature. This was followed by incubation
with appropriate biotynylated secondary antibodies for 30 min and
than streptavidin-biotin complex (LSAB2/HRP; DakoCytomation,
Denmark) or avidin-biotin complex (ABComplex/HRP; Novocas-
tra) for 30 min at room temperature, for syndecan-1 and cathepsin
D, respectively. For cathepsin K, DakoEnvision+TM/HRP kit
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(DakoCytomation) was applied in the same conditions. After each
step, slides were washed with TBS. The specific immune reactions
were visualized by 3',3-diaminobenzidine tetrahydrochloride
(DAB) (DakoCytomation). Sections were then counterstained with
Mayer's haematoxylin. Slides treated in the same way, but with
omission of primary antibodies, were used as negative controls.
The following tissue samples were applied as a positive control:
vaginal part of uterine cervix for syndecan-1, ductal breast carci-
noma – known to be strongly cathepsin D positive, and osteochon-
droma for cathepsin K. Immunohistochemical reaction was evalu-
ated separately in tumor and stroma by light microscope (Olympus
BX45; Japan) equipped with the eye grid. The percentage of posi-
tively-stained cells of each category was calculated in approxi-
mately 2000 cells of the some type in randomly selected areas
using objective x40 and included the following categories: no pos-
itive stained cells or less then 10%, 10-50% of positively-stained
cells and more than 50% of positively-stained cells. For statistical
analysis a case was classified as positive if at least 10% of the cells
were positively-stained. All slides were examined independently by
two experienced pathologists (J.S., E.K.) without knowledge of the
patient's outcome. In cases of disagreement, the slides were
reviewed with a double-headed microscope to achieve a consensus. 
Statistical analysis. Statistical differences between variables were
evaluated using Fischer exact test. Kenndall Tau test was applied
for assessment of correlation between variables. Survival rates
were calculated using Gehan and log-rank test. P values less than
0.05 were considered significant. Data was analysed by
STATISTICA 5.0 on an IBM compatible computer.
Results
Normal stratified squamous epithelium of the esophagus
revealed strong positive membrane syndecan-1
immunostaining of parabasal and intermediate layers
that decreased in more superficial layers. The staining
was weak on the apico-lateral aspects of basal layer
cells, and absent on the basal aspect. Esophageal glands
showed weak cytoplasmic staining. A strong reaction
was noted in plasma cells. In 3 cases, in which in situ
carcinoma was present at the edges of invasive ESCC,
syndecan-1 expression was markedly reduced when
compared to normal epithelium and the staining was
stronger in superficial layers. 32 (82.05%) of the 39
ESCCs were syndecan-1-positive (Fig.1A-B). The
staining pattern was predominantly membranous in
56.25% of the cases and mixed membranous and dif-
fuse cytoplasmic in 43.75%. In better-differentiated
areas of tumors, cancer cells recapitulated zonal
expression of syndecan-1 typical of normal squamous
epithelium. Syndecan-1-positive cases were signifi-
cantly (p<0.05) more frequent among well and moder-
ately differentiated ESCCs. There were no statistically
significant association between epithelial syndecan-1
expression and other clinicopathological findings
(Table 1). Syndecan-1 stromal reactivity was seen in 20
cases (51.28%) (Fig. 1A-B) and it was stronger among
cancer foci and in close vicinity to advancing tumor
margins. A positive stromal reaction correlated exclu-
sively with syndecan-1 positive cancer cases
(τ=0.4799) and distant metastasis (τ=0.4543).
Normal esophageal squamous epithelium and in
situ carcinoma were cathepsin D-negative, but the
glands were weakly positive. Cathepsin D immunore-
activity was revealed in 22 cases of ESCCs (56.41%)
(Fig. 1C-D). In 72.72% of the cases, positive cancer
cells were located in the most external parts of tumor
foci. Observations in the remaining samples showed a
homogenous staining of a majority of tumor cells (Fig.
1C). No statistically significant differences were noted
between cancer cathepsin D-positive and -negative
cases and all the studied clinicopathological findings
(Table. 1). However, significant correlations were
revealed between epithelial cathepsin D-positive stain-
ing and stromal cathepsin D- and epithelial cathepsin
K-positive staining (τ=0.5915 and τ=0.2499, respec-
tively), distant metastasis (τ=0.2315), and prominent
desmoplasia (τ=0.2315). Distinct stromal positive
cathepsin D staining was seen in 20 cases (51.28%)
(Fig. 1C-D). An especially strong granular cytoplas-
mic staining was noted in macrophages that infiltrated
the cancer area.  Distribution of strong positive fibrob-
lasts was similar to those of syndecan-1 samples.  Stro-
mal cathepsin D expression was statistically more fre-
quent in tumors with as infiltrative, as opposed to
expansive, growth pattern (p<0.05) (Table 1). Positive
stromal cathepsin D staining statistically correlated
with a positive cathepsin D cancer staining
(τ=0.5915), a distant metastasis (τ=0.2734), and an
infiltrative growth pattern (τ=0.3374).
Normal squamous epithelium, esophageal glands,
and in situ carcinoma were cathepsin K-negative.
Cathepsin K immunoreactivity was noted in only 12
studied cases of ESCCs (30.77%) (Fig. 1E). The reac-
tion was confined to relatively sparse cancer cells
located externally in tumor foci. Positive cathepsin K
epithelial staining correlated with positive cathepsin K
stromal (τ=0.2743) and cathepsin D epithelial
(τ=0.2499) staining, prominent desmoplasia
(τ=0.3316), and an expansive growth pattern
(τ=0.2642). Stromal cathepsin K staining was found in
18 cases (46.15%) (Fig. 1E-F). Strong granular cyto-
plasmic staining was observed in macrophages, espe-
cially in osteoclast-like multinucleated giant cells,
seen mainly at the edges of keratinized cancer foci
(Fig. 1F). Relative to cathepsin D, a smaller number of
macrophages exhibited cathepsin K reactivity. The
intensity of fibroblast staining was weak. Similar to
cancer immunoreactivity, no statistically significant
differences between stromal cathepsin K-positive and
-negative cases and all the clinicopathological findings
were noted (Table 1). Cathepsin K stromal immunoex-
pression significantly correlated with positive epithe-
lial cathepsin K staining (τ=0.2743) and a better dif-
ferentiation of tumors (τ=0.3090).
The only factors that significantly influenced one-
year survival in the study group were cancer cathepsin D
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staining and distant metastasis (p<0.05). In patients with
ESCC, who survive one year after the surgery, the per-
centage of cases with negative cancer cathepsin D stain-
ing (Fig. 2) and without features of distant metastasis,
was higher.
Discussion
The current study demonstrated immunoexpression of
three molecules that are probably involved in tumor
growth and dissemination in advanced ESCCs. 
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Fig. 1. Positive (A, C, E) and negative (B, D, F) epithelial immunohistochemical reaction for syndecan-1 (A, B), cathepsin D (C, D) and
cathepsin K (E, F), respectively. Positive stromal reactions for all antigens studied (original magnification ×10).
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Table 1. Relation between immunoexpressions of syndecan-1 and cathepsins D and K and selected clinicopathological findings in patients
with esophageal squamous cell carcinoma
(1) median; (2) pT2, pT3, and pT4 spread to muscularis propria, adventitia, and adjacent structures, respectively; (3) pN0, and pN1, absence, and presence of
lymph nodes metastasis, respectively; (4) pM0, and pM1, absence, and presence of distant metastasis, respectively; (5) stage II = T2-3 N0 M0 or T1-2 N1 M0,
stage III = T3 N1 M0 or T4 N0-1 M0, stage IV = T1-4 N0-1 M1; (6) G1 – well-, G2 – moderately-, and G3 – poorly differentiated ESCC; (*) p<0.05
Positive epithelial syndecan-1 immunoexpression
was seen in over 80% of cases. Except positive direct
relation with histological grading of cancers, no sig-
nificant associations between syndecan-1 expression
and clinicopathological parameters were revealed. A
similar correlation with tumor differentiation was also
seen in the squamous cell carcinoma of various loca-
tions e.g., of head and neck [16,17], and uterine cervix
[18] as well as in adenocarcinomas including that of
the stomach [19], large intestine [20], liver (both hepa-
to- and cholangiocellular carcinomas) [21,22], kidney
[23] and endometrium [24]. These proved the impor-
tance of epithelial syndecan-1 in maintaining differen-
tiating phenotypes, not only in physiological condi-
tions, but in a variety of neoplasms as well. This was
supported by experimental findings [5]. It was
observed that suppression of syndecan-1 expression on
epithelial cells by transfection with antisense cDNA
caused profound changes in cell morphology. A flat-
tened, cuboidal shape, typical of epithelial cells, was
replaced by an elongated fusiform shape, which was
accompanied by the ability to migrate in collagen gels
as well as anchorage-independent growth [5]. It should
be stressed that in many tumors mentioned above, neg-
ative syndecan-1 expression correlated with at least
some of the unfavorable markers like more advanced
stage, deeper level of infiltration, vascular invasion,
lymph node, or distant metastasis [19-25]. An abnor-
mal expression of syndecan-1 was also revealed in pre-
cursor lesions. In the present study, a reduction in the
expression and its localization in more superficial lay-
ers, was noted in in situ carcinoma of the esophagus
that was also seen in other organs lined with squamous
epithelium [17]. Lost of syndecan-1 expression was
observed in colorectal adenomas and endometrial
hyperplasia [26]. These findings confirmed the signif-
icant role of syndecan-1-status, not only during cancer
dissemination, but also in the early, intraepithelial
stage as well. It seems that the decrease of syndecan-1
expression in neoplastic cells influenced their growth
and morphology and caused a reduction of cell-cell,
followed by cell-matrix interactions. This phenome-
non precluded and influenced the reduction of another
adhesion molecule expression – E-cadherin [19,26].
Such changes facilitate cancer cell migration and stro-
mal infiltration, as well as vascular invasion and
metastasis. However, enhanced syndecan-1 expression
correlated with increased aggressiveness and a poor
clinical outcome in breast [27], prostate [28] and
nasopharyngeal cancers [29]. This dualistic role of
syndecan-1 in carcinogenesis may be the consequence
of a tissue and/or tumor stage-specific function, and
reflects multiple functions of the molecule [6]. 
Contribution of cathepsin D in growth and dissem-
ination of various tumors was extensively studied.
Increased cathepsin D immunostaining was detected in
some precursor lesions, e.g., in grade III endometrial
adenomatous hyperplasia [30] or colorectal adenomas
[31]. Some reports revealed increased cathepsin D
activity in serum and/or tumor homogenates, especial-
ly in malignancies [32]. Strong cathepsin D immuno-
expression was found in nasopharyngeal [33], oral
[34], gastric [35], colorectal [31], renal [36], breast
[37] and ovarian [38] carcinomas. In our study, posi-
tive cathepsin D staining in cancer cells was found in
slightly more than half of the ESCCs cases. Although
no significant differences between cathepsin D-posi-
tive and -negative cases with respect to studied clini-
copathological features were revealed, the majority of
patients who survive one year after the surgery were
characterized by cathepsin D negative cancer staining.
Epithelial expression correlated with distant metastasis
and prominent desmoplasia. These findings may sug-
gest the influence of cathepsin D over ESCCs inva-
siveness. Despite differences in the examined group,
especially as far as the number of cases, staging and
outcome are concerned, our results were partly sup-
ported by the only report a ESCC by Ikeguchi et al.
[39]. Epithelial cathepsin D imunoexpression was
noted in 49% of ESCCs. It was significantly associat-
ed with a tumor invasive growth pattern, poor progno-
sis, and nuclear accumulation of p53 protein, but
cathepsin D expression was not recognized as an inde-
pendent prognostic factor in multivariate survival
analysis. Correlating with the majority of our cases,
cathepsin D-positive cancer cells were usually present
at the advancing margins rather than in the central part
of the tumor. Many experimental studies gave evi-
dence of the potential role of cathepsin D in tumor
invassivenes and metastatic ability. It was proven that
cathepsin D may directly participate in ECM degrada-
tion after its release from cells and its autoactivation at
low pH, typical of tumor stroma, or indirectly via acti-
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Fig. 2. One-year survival of patients with esophageal squamous
cell carcinoma according to epithelial cathepsin D status. 
vation of a cascade of other proteases like cathepsin B,
L, plasminogen activators, plasmin and matrix metalo-
proteases [8]. Furthermore, cathepsin D as a mitogen,
together with various factors, released from the dam-
aged ECM or from tumor-associated macrophages and
other inflammatory cells could directly stimulate can-
cer growth and angiogenesis [7]. In fact, the positive
correlation of epithelial cathepsin D expression with
lymph node or distant metastasis, as well as with
advanced stage was reported [31-35]. It is worth men-
tioning however, that in renal cell carcinomas strong
cathepsin D imunoexpression was associated with a
significantly lower incidence of distant metastasis and
an improved long-term survival [36].
According to our knowledge, the current study is
the first to describe the immunoexpression of cathep-
sin K in ESCCs. Cathepsin K was found in sparse can-
cer cells in almost 1/3 of the cases. Its expression cor-
related with the expansive growth pattern and promi-
nent desmoplasia. It is interesting that epithelial
cathepsin K was detected in malignancies known for
their special propensity to bone metastases like cancer
of prostate [12], breast [10] and lung [13]. In ESCCs
bone metastases are also relatively common and occur
in 9-20% of cases [14]. Based on cathepsin K mRNA
and protein expression in prostate cancer cell lines and
tissue samples, Brubaker et al. [12] indicated that in
primary sites, cathepsin K may promote cancer dis-
semination, but in osseous metastasis, it is involved in
degradation of ECM. However, in the present study,
significant differences in cathepsin K expression with
respect to nodal and distant metastasis were not
revealed. It is worth mentioning that cathepsin K is
characterised by strong and unique proteolytic activity
and is able to breakdown bone matrix components i.e.,
type I collagen, osteopontin and osteonectin [9]. It is
not surprising that the protease is engaged in bone
destruction in many non-epithelial tumours and
tumour-like conditions e.g. osteosarcoma [40] or giant
cell tumour [41]. The cathepsin released by osteoclasts
and tumor cells degrades bone matrix but also may
participate in the establishment of micrometastases
and lead to the release of factors supporting tumor
growth [12]. 
It is interesting that in the current study stromal
expressions of all the macromolecules were a frequent
finding, revealed in approximately half of samples.
Stromal cathepsin D immunoexpression was statisti-
cally more frequent in tumors with an infiltrative
growth pattern. Furthermore, syndecan-1 and cathep-
sin D expression correlated with distant metastasis,
but cathepsin K was associated with better differenti-
ation of tumors. Syndecan-1 was also detected in the
stroma of colorectal [20], pancreatic [42], endometri-
al [24], and head and neck [17] cancers. A few authors
reported its association with poor prognosis [20,42].
On the other hand, in invasive breast cancers, positive
stromal cathepsin D immunoexpression was common
and linked with unfavorable prognostic markers, i.e.,
advanced tumor stage, lower grade of differentiation,
and a high proliferative index, in addition to poor
patient outcome [37]. In submucosal colorectal carci-
noma, a positive stromal reaction was associated with
lymph node metastasis [31]. However, surprisingly, it
was an independent prognostic factor for prolonged
disease-free survival in invasive ovarian cancers
[38]. Cathepsin K-positive fibroblasts and tumor-
associated macrophages were found in aggressive
histological types of lung adenocarcinoma
(acinar/papillary and mixed type) [13] and in ductal
breast carcinoma [10]. All these results, with the
addition of those reported in the current study, seem
to confirm the important and complex role of the
stroma in cancer dissemination. It is well-known that
inflammatory cells seen at the invasive margins act
either as a defense mechanism against the tumor or,
due to various enzymes including cathepsin, can
destroy tissue architecture and promote tumor inva-
sion [31]. The expression of cathepsins on the other
stromal cells may be involved in the remodeling of
stroma within and around the primary tumor, limiting
or facilitating its spread. It is also very likely that the
promotion of growth reported in some stromal synde-
can-1-positive neoplasms is, at least in part, the con-
sequence of storing and presenting heparin-binding
growth factors to tumor cells [5,20]. 
In conclusion, the results of the currant study indi-
cate the association of both epithelial and stromal syn-
decan-1 and cathepsins D and K status with growth
and invasion of esophageal squamous cell carcinoma.
However, further studies on a larger and more hetero-
geneous population, especially as far as staging is con-
cerned, are required to elucidate the usefulness of
these molecules as markers of progression and prog-
nosis, or even as modes of therapy in patients with the
cancer. 
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